Organon & Co | OGN - Cash And Equivalent



Organon & Co reported $599M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Adcock Ingram Holdings ZAR 79.14M 10.28M Dec/2024
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Celltrion KRW 829.07B 829.07B Mar/2025
Cspc Pharmaceutical 6.78B 1.6B Dec/2024
Dianthus Therapeutics USD 13.24M 9.56M Jun/2025
Divis Laboratories Ltd 4.15B 31.87B Mar/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
Kangmei Pharma CNY 894.14M 120.63M Mar/2025
Knight Therapeutics CAD 5.81M 3.59M Sep/2024
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.62M 7.88M Dec/2024
Merck USD 8.01B 622M Jun/2025
Neuren Pharmaceuticals AUD 3.15M 582K Dec/2024
Novartis USD 6.66B 4.8B Jun/2025
Organigram Holdings 35.88M 8.42M Jun/2025
Organon & Co USD 599M 52M Jun/2025
Pharma Mar EUR 21.59M 38.7M Jun/2025
Qiagen NV USD 733.82M 95.06M Jun/2025
Sartorius EUR 819M 20.5M Jun/2025
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Tilray USD 189.7M 15.49M Nov/2024